San Francisco, CA—Reductions in postinitiation treatment costs partly offset, but did not eliminate, the added cost of repository corticotropin injection (RCI) therapy for patients with systemic lupus erythematosus (SLE), researchers behind the analysis of an administrative claims database have found.
Chicago, IL—In a recent press release by the American Medical Association (AMA), the organization announced the launch of 8 new educational modules to enable practice improvement and promote innovation in the delivery of care.
London, United Kingdom—Women with systemic lupus erythematosus (SLE) appear to have a higher risk for cervical cancer and premalignant cervical changes compared with women in the general population, according to the results of a large Swedish registry study presented at the 2016 annual meeting of the European League Against Rheumatism (EULAR). The highest risk was observed in women treated with immunosuppressive agents compared with those treated with antimalarial medications, the researchers also observed.
London, United Kingdom—Evidence is mounting in support of using the investigational monoclonal antibody anifrolumab in patients with severe systemic lupus erythematosus (SLE). Results from the phase 2b MUSE trial—which were first presented at the 2015 American College of Rheumatology Annual Scientific Meeting, and then in greater detail at the recent 2016 European League Against Rheumatism Annual Congress—show that in patients with moderate-to-severe SLE, anifrolumab reduces disease activity across a wide range of clinical end points, and is safe and tolerable.
London, United Kingdom—An early-phase study of bimekizumab, a monoclonal antibody potently and selectively inhibiting interleukin (IL)-17A and IL-17F, demonstrated strong responses in skin and joints of patients with psoriatic arthritis. IL-17A and IL-17F, key proinflammatory cytokines, are overexpressed in psoriatic skin lesions, said Sophie Glatt, MD, UCB Celltech, Slough, United Kingdom, in an oral presentation at the 2016 European League Against Rheumatism Annual Congress.
London, United Kingdom—Ixekizu­mab (Taltz) achieved clinically significant improvement in the signs and symptoms of psoriatic arthritis (PsA), including arthritis, dactylitis, and enthesitis, as well as skin improvements, during a 28-week extension phase of a 24-week, double-blind, phase 3 trial called SPIRIT-P1 (totaling 52 weeks).
London, United Kingdom—The presence of depression in patients with juvenile idiopathic arthritis (JIA) is associated with more severe pain, and disability at baseline and in the future, according to data from the Childhood Arthritis Prospective Study (CAPS) presented at the 2016 European League Against Rheumatism Annual Congress in June.
Page 2 of 2
Results 11 - 17 of 17
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology